Achalasia, Achalasia Cardia
Conditions
Keywords
Heller Laparoscopic, Dor Laparoscopic
Brief summary
The goal of this prospective observational study is to evaluate the role of nasogastric tube (NGT) in patients with achalasia underwent to Heller-Dor laparoscopic. The main question it aims to answer are: • If it is possible to remove NGT at the end of surgery. Participants will be dived in two groups: the first one with NGT after surgery and second one without NGT (noNGT). If there is a comparison group: Researchers will compare group NGT and group noNGT to see if routine placement of NGT is useless.
Detailed description
Achalasia is a rare disease characterized by dysfunction of low oesophageal sphincter. This disease is divided according to Chicago classification into three subtypes. Laparoscopic Heller - Dor is a important treatment of types I and II Achalasia. There are several studies evaluating the NGT in colorectal, hepatic, urologic, thoracic, otorhinolaryngology, gastric and esophageal surgery. Its use in postoperative period in achalasic patients is not yet clear. Historically, NGT has been used to reduce gastric distention, nausea, vomiting and chest pain. The aim of our study is to value the role of NGT for this surgery. We prospectively enrolled achalasic patients undergoing laparoscopic Heller -Dor . The NGT group and noNGT were compared in terms of perioperative outcomes.
Interventions
PROCEDUREnasogastric tube
The intervention consists in removing or not the nasogastric tube at the end of the surgery.
Sponsors
Federico II University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients with achalasia of type I and II * patients undergoing laparoscopic Heller-Dor * patients older than 18 years * both sexes
Exclusion criteria
* pregnant patients; * patients a history of abdominal surgery; * body mass index (BMI) \>40; * American Society of Anesthesiology (ASA) score \>4; * megaesophagus; * III type Achalasia; * previously treated for this disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Nausea | in the first postoperative day | clinically evaluating the presence or absence |
| vomiting | in the first postoperative day | clinically evaluating the presence or absence |
| chest pain | in the first postoperative day | clinically evaluating the presence or absence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intake semi-solid diet (day) | from the first postoperative day to the third postoperative day | when the patient starts to eat |
| Length of stay | from the first postoperative day to the third postoperative day | days of hospitalization from first postoperative day |
| postoperative complications | from the first postoperative day to the third postoperative day | Based on Clavien-Dindo classification |
| First flatus | from the first postoperative day to the third postoperative day | on which postoperative day the patient had the first flatus. |
| Intake liquid diet | from the first postoperative day to the third postoperative day | when the patient starts drinking |
Countries
Italy
Outcome results
None listed